CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
NORCROSS, Ga., March 05, 2018 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected].
